Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation, alleging misleading representations and failure to disclose adverse business facts during the specified Class Period from July 25, 2024, to October 22, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities during the Class Period [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Integer - The complaint alleges that Integer overstated its competitive position and failed to properly disclose worsening sales of electrophysiology devices [3]. - It is claimed that Integer mischaracterized its growth drivers, contributing to misleading information provided to investors [3]. Group 3: Stock Price Impact - Following a sales guidance reduction announced on October 23, 2025, Integer's stock price fell by $35.22 per share, representing a decline of more than 32% in a single trading day [4].

Core Viewpoint - Hagens Berman is notifying investors about a pending securities class action against F5, Inc. due to allegations of misleading the market regarding the security of its BIG-IP products, which resulted in significant financial losses for investors [1][2]. Group 1: Allegations and Impact - The lawsuit claims that F5 executives misled the market about the security of its core products, particularly after a sophisticated nation-state threat actor allegedly gained long-term access to F5's systems and exfiltrated sensitive source code [2][8]. - Following the revelation of the security breach in October 2025, F5's market value plummeted by over $2 billion, with stock prices declining nearly 14% over two trading days [2][8]. - F5's disappointing Q4 FY25 results, released on October 27, 2025, indicated a significant reduction in expected sales and renewals, leading to a further drop in stock price by $22.83 (-7%) the next day [8]. Group 2: Legal Proceedings and Deadlines - The lead plaintiff deadline for the class action is set for February 17, 2026, with the class period defined as October 28, 2024, to October 27, 2025 [5][7]. - The core allegation centers around the undisclosed breach of BIG-IP source code, which is critical to F5's revenue generation [5][8]. Group 3: Company Performance and Future Outlook - The lawsuit highlights that F5's claims of having a best-in-industry security platform were misleading, as the company was facing a significant security incident that jeopardized both client security and F5's future prospects [8]. - The ongoing remediation efforts and the impact of the security breach have led to elongated sales cycles and increased expenses, further complicating F5's financial outlook for fiscal 2026 [8].

Core Viewpoint - A class action lawsuit has been filed against SLM Corporation (Sallie Mae) for allegedly concealing a significant increase in loan delinquencies during a specific period, leading to investor losses [1][3]. Group 1: Lawsuit Details - The lawsuit represents investors who acquired Sallie Mae securities from July 25, 2025, to August 14, 2025 [1]. - Investors have until February 17, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations - The complaint claims that Sallie Mae misled investors about the rising early-stage delinquencies, attributing them to seasonal trends while downplaying the effectiveness of their loss mitigation and loan modification programs [3]. - A report from TD Cowen on August 14, 2025, revealed that July delinquencies increased by 49 basis points month-over-month, which was higher than expected for that season [4]. Group 3: Market Reaction - Following the revelation of the delinquency spike, Sallie Mae's stock price fell by $2.67 per share, or 8.09%, closing at $30.32 on August 15, 2025 [4].

Core Points - A class action lawsuit has been filed against CoreWeave, Inc. and certain senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1][3] - Investors are encouraged to seek additional information regarding the lawsuit and their legal options [2][9] Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure [4] - The company relies on partnerships, notably with Core Scientific, to develop its data centers [4] Allegations and Stock Performance - CoreWeave allegedly overstated its ability to meet customer demand and concealed significant construction delays at its data centers [5] - On October 30, 2025, CoreWeave's stock dropped by $8.87 per share (over 6%) after the merger agreement with Core Scientific was terminated due to insufficient shareholder votes [6] - Following a revenue guidance reduction on November 10, 2025, the stock fell by $17.22 per share (over 16%) due to delays from a third-party data center developer [7] - A report on December 15, 2025, indicated further delays in a major data center project, causing the stock to drop by $2.85 per share (over 3%) [8]

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Company Overview - Ardent Health operates acute care hospitals and other healthcare facilities, with a focus on the collection of accounts receivable [4]. Allegations of Fraud - The lawsuit claims that Ardent Health misrepresented its process for determining the collectability of accounts receivable, stating it relied on "detailed reviews of historical collections," while in reality, it used a "180-day cliff" method that inflated reported accounts receivable and delayed loss recognition [4]. Stock Performance Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 on November 13, 2025 [5]. Legal Proceedings - Investors have until March 9, 2026, to request to lead the case in the U.S. District Court for the Middle District of Tennessee, with the case titled Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. Law Firm Background - Bleichmar Fonti & Auld LLP, the law firm representing the plaintiffs, is recognized for its success in securities class actions and has recovered significant amounts for clients in past cases [7].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and certain senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York, under the case caption West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al. [3].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Plug Power specializes in hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets, and develops infrastructure such as hydrogen production plants [4]. Legal Proceedings - Investors have until April 3, 2026, to request to lead the case, which is pending in the U.S. District Court for the Northern District of New York, captioned Ortolani v. Plug Power Inc., et al. [3]. Financial Impact - Plug Power announced a $1.66 billion loan guarantee from the U.S. Department of Energy to finance the construction of hydrogen production projects, but allegedly overstated the likelihood of receiving these funds [4]. - The stock price dropped significantly following key announcements: - On October 7, 2025, the abrupt departure of CEO Andrew Marsh and President Sanjay Shrestha led to a 6.3% drop, from $4.13 to $3.87 per share [5]. - On November 10, 2025, the suspension of activities under the DOE loan program caused a 3.4% drop, from $2.65 to $2.56 per share [6]. - On November 14, 2025, confirmation of the suspension of plans to construct hydrogen facilities resulted in a 17.6% drop, from $2.49 to $2.25 per share [7].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Picard Medical, Inc. securities during the specified Class Period, highlighting potential investor compensation opportunities [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between September 2, 2025, and October 31, 2025 [1]. - Investors who purchased Picard Medical securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Picard Medical - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Picard's business and operations [4]. - Specific allegations include involvement in a fraudulent stock promotion scheme, use of offshore accounts for share dumping, and omission of critical information regarding false rumors and artificial trading activity [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3].

Core Viewpoint - A class action securities lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud affecting investors between August 3, 2023, and December 26, 2025 [1] Group 1 - The lawsuit is initiated by Kahn Swick & Foti, LLC and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr. [1] - The action seeks to recover losses for investors adversely affected by the alleged fraud [1]

Core Viewpoint - Ademi LLP is investigating potential securities fraud claims against IonQ, Inc. due to possible inaccuracies in statements regarding its business operations and prospects [1] Group 1: Investigation Focus - The investigation is centered on whether IonQ's reported revenues were reliant on federal government "backdoor earmarks" [2] - There are concerns that IonQ may have inflated both the amount and nature of its revenue [2] - The investigation also examines the sale of nearly $400 million worth of IonQ stock by its executives [2]